Skip to content
AnalystLens

Merck Annual Report (Amendment), Year Ended Dec 31, 2004

Filing Date
Filed March 31, 2005
Period End
December 31, 2004
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Aug ’21Aug ’21
  4. Restructuring8-K · Jul ’25Jul ’25

Summary

Summary of the 10-K/A filed March 31, 2005. Cited figures are marked; the original filing is the authoritative source.

This is not Merck's annual report.

The filing is Amendment No. 1 to Schering-Plough Corporation's Form 10-K for fiscal 2004 (filed under MRK-related context, but the registrant is Schering-Plough). It was filed to add audited combined financial statements for 2004 and unaudited combined financial statements for 2003 for the Merck/Schering-Plough Cholesterol Partnership, as required by Rule 3-09 of Regulation S-X. No other parts of the original 10-K are amended, so it does not contain Merck's or Schering-Plough's consolidated results, risk factors, or MD&A.

The Partnership holds the joint commercialization rights to ezetimibe, marketed as ZETIA and EZETROL, and to its combination with simvastatin, marketed as VYTORIN and INEGY. Reported 2004 combined net sales were $1,214 milliona. The U.S. accounted for about 83% of 2004 sales, down from 88% in 2003.

Partners' capital was a deficit of $66 millionb at December 31, 2004, after distributions of $855 million to the partners in 2004. The statements reflect only expenses contractually agreed to be shared, so they are not a complete picture of a standalone company's costs. Deloitte & Touche issued an unqualified opinion on the 2004 statements dated March 30, 2005.

The 2003 figures are unaudited. For investors, the filing is most useful as a supplemental look at the economics of the ZETIA/VYTORIN collaboration.

It shows high cash distributions relative to a small partners' deficit, substantial concentration of receivables (three customers held about 80%c of year-end receivables), and reliance on the partners' infrastructure. It is not a standalone earnings or valuation document for either parent company.

Key Highlights

  1. Filing type correction: this is a 10-K/A from Schering-Plough Corporation, not Merck, amending only Item 15 to add Rule 3-09 financial statements.
  2. Partnership net sales of ZETIA/VYTORIN and related products were $1,214 million in 2004.
  3. U.S. sales were about 83% of combined 2004 net sales, versus 88% in 2003, indicating growing international share.
  4. Partners' capital was a $66 million deficit at December 31, 2004, with $855 million distributed to partners in 2004 and $926 million in 2003.
  5. Three customers accounted for roughly 80% of Partnership accounts receivable at year-end 2004, with minimal historical bad debts.
  6. Deloitte & Touche gave an unqualified opinion on the 2004 combined statements (report dated March 30, 2005); the 2003 statements are unaudited.
  7. The statements include only contractually agreed expenses, so they do not represent full standalone costs and may differ materially from future results.

Frequently Asked Questions

  1. Why was this filing amended, and what changed?

    Schering-Plough amended its 2004 Form 10-K only under Item 15 to add audited combined financial statements for the 2004 year and unaudited 2003 statements for the Merck/Schering-Plough Cholesterol Partnership, per Rule 3-09 of Regulation S-X. No other portions of the original 10-K were changed.

  2. What does the Cholesterol Partnership sell?

    The Partnership jointly develops and markets ezetimibe (ZETIA in the U.S., EZETROL in most other countries) and a combination of ezetimibe and simvastatin (VYTORIN in the U.S., INEGY in many other countries). Its products are approved in the U.S. (ZETIA in October 2002, VYTORIN in July 2004) and launched in more than 50 and 15 countries outside the U.S., respectively.

  3. Why does the Partnership show a deficit in partners' capital despite large sales?

    Partners' capital is a $66 million deficit at year-end 2004 because the Partnership distributes most of its cash to Merck and Schering-Plough, with $855 million distributed in 2004. The combined statements also reflect only the costs contractually shared under the agreements, so reported profit and distributions are not directly comparable to a standalone company.

  4. How concentrated is the Partnership's customer base and revenue?

    Three customers represented about 80% of accounts receivable at December 31, 2004. The U.S. generated about 83% of 2004 combined net sales (88% in 2003). Bad debts have been minimal, and the Partnership generally does not require collateral on credit sales.

  5. Do these statements represent the full financial picture of Merck or Schering-Plough?

    No. The statements cover only the Partnership's activities and the expenses the partners agreed to invoice to it. Other partner costs, such as local sales forces outside the U.S., corporate overhead, and interest, are excluded, and the statements are not a complete presentation of a stand-alone pharmaceutical company's results. Investors should refer to each parent's consolidated filings for full financial information.